Business Context and Reporting Period
This Form 6-K filing by Trinity Biotech PLC covers the month of June 2026. The registrant, a foreign private issuer based in Bray, County Wicklow, Ireland, is reporting on corporate actions regarding its capital raising activities and the termination of a prior sales agreement.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the execution of an equity offering program.
Material Changes
- New ATM Agreement: On June 12, 2026, the Company entered into an At the Market Offering Agreement with Lucid Capital Markets, LLC, authorizing the sale of up to $4,352,314 of American Depositary Shares (ADSs).
- Commission Structure: The Company agreed to pay Lucid a commission of 3.0% of the gross sales price of ADSs sold under the new agreement.
- Termination of Prior Program: On June 2, 2026, the Company terminated its previous At the Market Offering Agreement with Craig-Hallum Capital Group LLC. The prior program had been inactive since March 2025.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond standard legal disclaimers regarding the sale of securities. The Company noted that sales under the new agreement will be made pursuant to a previously filed Registration Statement on Form F-3 (File No. 333-280391).
Investor Verification Checklist
- Verify the actual volume and timing of ADS sales executed under the new Lucid Capital Markets agreement.
- Confirm the impact of the 3.0% commission on net proceeds from future sales.
- Review the Company's cash position and capital needs to understand the urgency of the new ATM program.
- Check for any subsequent filings regarding the execution of sales under the terminated Craig-Hallum program prior to its termination.